we should be flying. . ., page-23

Whenever speaking to potential investors, I reckon Alchemia management should be referencing the successful ISIS Pharmaceuticals Antisense Platform and Business model and SP performance.

The ISIS Partner Model is not identical to Alchemia's HyACT and VAST model and the drug platform is completely different, but plenty of similarities and all keen US Biotech investors know about ISIS.

http://www.isispharm.com/Pipeline/index.htm

In a little over a year, ISIS has flown from a Market Cap of $800m to almost $6b. They have just one approved drug (it scraped over the line), but it appears the company is attracting investor interest because of the potential - their Platform is spread amongst a number of partners.

If Alchemia can get its first combo drug approved and then replicate the pipeline process with other partners, even prior to approval, there is no reason why, once listed on Nasdaq, Alchemia could not replicate the success of ISIS...

...and things can change quite quickly given suitable momentum - and the key to all this - a proven technology and business savvy management.